AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020
Dec 17, 2020
31868_dirs_2020-12-17_3992871d-746b-454b-9081-c047cac1fd85.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-12-15
Reporting Person: Gayer Charles K (Vice President and CCO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-15 | Emp. Stock Option (Right to Buy) | $8.31 | A | 190000 | Acquired | 2030-12-15 | Common Stock (190000) | Direct |
Footnotes
F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20